Fitzpatrick Prevails in Patent Infringement Suit

Fitzpatrick Wins Patent Infringement Suit on Behalf of Bristol-Myers and Sanofi Against Apotex over Generic Plavix
June 21, 2007

For Immediate Release

William Briganti / Rosemarie Yu
(212) 704-8214 / 642-7781

NEW YORK, June 21, 2007 – Leading intellectual property firm Fitzpatrick, Cella, Harper & Scinto announced its victory on behalf of clients Bristol-Myers Squibb Co. and Sanofi-Aventis SA in their patent infringement suit against Apotex Inc. concerning Apotex’s attempts to market a generic version of Plavix®, one of the world’s largest-selling pharmaceutical products. Plavix® prevents heart attacks by keeping blood platelets from sticking together.

U.S. District Judge Sidney Stein in New York ruled that Apotex failed to prove by clear and convincing evidence that the patent covering the active ingredient in Plavix® is invalid or unenforceable, and granted plaintiffs’ request for a permanent injunction.

Fitzpatrick Cella attorneys involved in the case include partners Robert Baechtold, John Murnane and William Solander.

Fitzpatrick, Cella, Harper & Scinto, founded in 1971, is an intellectual property law firm with offices in New York, Costa Mesa, California and Washington, D.C., of approximately 140 lawyers. The firm’s practice covers the spectrum of intellectual property services, including patents, trademarks, copyrights, unfair competition, and trade secrets. Fitzpatrick represents an international client base from Fortune 500 companies to start-up companies.